Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance
pharmaphorum
APRIL 23, 2021
billion in milestone payments in the deal, which will focus on using small-molecule compounds to “fine tune” the effects of genetic medicines in the body. The approach relies on the use of drug responsive domains (DRDs) on the gene-editing medicine, which can be used to either increase or decrease protein expression.
52 
Let's personalize your content